Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Oramed Pharmaceuticals Inc is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$22.06|
|52-week range||$2.40 - $24.25|
|50-day moving average||$19.95|
|200-day moving average||$14.37|
|Wall St. target price||$23.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-2.52%|
|1 month (2021-09-16)||5.70%|
|3 months (2021-07-16)||79.35%|
|6 months (2021-04-16)||161.07%|
|1 year (2020-10-16)||723.13%|
|2 years (2019-10-16)||602.55%|
|3 years (2018-10-16)||410.65%|
|5 years (2016-10-14)||210.70%|
|Revenue TTM||$2.7 million|
|Gross profit TTM||$2.7 million|
|Return on assets TTM||-19.57%|
|Return on equity TTM||-36.39%|
|Market capitalisation||$735.8 million|
TTM: trailing 12 months
There are currently 1.1 million Oramed Pharmaceuticals shares held short by investors – that's known as Oramed Pharmaceuticals's "short interest". This figure is 5.7% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Oramed Pharmaceuticals shares can be evaluated.
Oramed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Oramed Pharmaceuticals shares currently shorted divided by the average quantity of Oramed Pharmaceuticals shares traded daily (recently around 783193.00699301). Oramed Pharmaceuticals's SIR currently stands at 1.43. In other words for every 100,000 Oramed Pharmaceuticals shares traded daily on the market, roughly 1430 shares are currently held short.
However Oramed Pharmaceuticals's short interest can also be evaluated against the total number of Oramed Pharmaceuticals shares, or, against the total number of tradable Oramed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oramed Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oramed Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0371% of the tradable shares (for every 100,000 tradable Oramed Pharmaceuticals shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oramed Pharmaceuticals.
Find out more about how you can short Oramed Pharmaceuticals stock.
We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.
Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.
Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $2.4 up to $24.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.8524. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.